Pembrolizumab

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Grade I Meningioma, Adult

Conditions

Grade I Meningioma, Adult, Grade II Meningioma, Adult, Grade III Meningioma, Adult, Recurrent Meningioma

Trial Timeline

Mar 25, 2021 → Apr 30, 2030

NCT ID

NCT04659811

About Pembrolizumab

Pembrolizumab is a phase 2 stage product being developed by Merck for Grade I Meningioma, Adult. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04659811. Target conditions include Grade I Meningioma, Adult, Grade II Meningioma, Adult, Grade III Meningioma, Adult.

What happened to similar drugs?

0 of 7 similar drugs in Grade I Meningioma, Adult were approved

Approved (0) Terminated (1) Active (6)

🔄diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3

❌MEK162, MEK inhibitor; oral + Physician's choice chemotherapyPfizerPhase 3

🔄rituximabBiogenPhase 3

🔄Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3

🔄Remestemcel-LMesoblastPhase 3

🔄remestemcel-LMesoblastPhase 3

🔄avutometinib + Defactinib + Pegylated liposomal doxorubicin + Paclitaxel + Letrozole + AnastrozoleVerastem OncologyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02083484	Pre-clinical	Completed	—	—	Melanoma
NCT07302347	Phase 1/2	Recruiting	Mar 31, 2026	Dec 31, 2029	Malignant Neoplasm
NCT07089992	Phase 2	Recruiting	Dec 4, 2025	Dec 1, 2028	Sarcoma
NCT07007273	Phase 2	Recruiting	Jun 20, 2025	Jul 1, 2030	Cutaneous Sarcoma
NCT04569461	Phase 2	Withdrawn	Jun 1, 2025	Dec 1, 2026	Prostate Cancer
NCT05815927	Phase 3	Recruiting	May 23, 2025	Mar 30, 2030	Oligometastatic Squamous Cell Carcinoma of the Head and Neck
NCT05852223	Phase 2	Recruiting	Dec 20, 2024	Dec 1, 2027	Differentiated Thyroid Cancer
NCT05879120	Phase 2	Withdrawn	Jul 30, 2024	Oct 2, 2024	Recurrent Glioblastoma
NCT06004336	Phase 2	Recruiting	Oct 31, 2023	Jan 1, 2029	Oligometastatic Renal Cell Carcinoma
NCT05496036	Phase 2	Recruiting	Feb 13, 2023	Sep 30, 2027	Merkel Cell Carcinoma
NCT05131919	Phase 2	Active	Dec 22, 2022	Jul 1, 2031	Colorectal Cancer
NCT05197322	Phase 2	Recruiting	Jul 20, 2022	Dec 1, 2028	Adenocarcinoma of the Colon
NCT05406713	Phase 2	Active	Jul 13, 2022	Jan 1, 2028	Muscle Invasive Bladder Carcinoma
NCT05025813	Phase 2	Recruiting	Jun 28, 2022	Jun 1, 2027	Cutaneous Squamous Cell Carcinoma of the Head and Neck
NCT06413095	Phase 1	Completed	Jun 1, 2022	Jun 22, 2023	Head and Neck Squamous Cell Carcinoma
NCT05191472	Phase 2	Terminated	May 3, 2022	Dec 31, 2023	Multiple Myeloma
NCT05204160	Phase 2	Withdrawn	Apr 11, 2022	Feb 27, 2024	Plasma Cell Myeloma
NCT04575961	Phase 2	Active	Feb 22, 2022	Mar 1, 2028	Ovarian Cancer
NCT04417166	Phase 2	Recruiting	Feb 11, 2022	Dec 1, 2026	Lymphoma, Extranodal NK-T-Cell
NCT05188508	Phase 2	Recruiting	Jan 14, 2022	Jan 1, 2027	Glioma

Competing Products

20 competing products in Grade I Meningioma, Adult

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	27
azenosertib	Zentalis Pharmaceuticals	Phase 2	32
Sepantronium Bromide	Cothera Bioscience	Phase 2	29
DS-1001b	Daiichi Sankyo	Phase 2	39
Rabeprazole Sodium	Eisai	Pre-clinical	26
Binimetinib 15 MG	Ono Pharmaceutical	Phase 2	42
Abemaciclib + Letrozole	Eli Lilly	Phase 2	42
Pirtobrutinib + Mosunetuzumab	Eli Lilly	Phase 2	42
Pembrolizumab + Pemetrexed + Abemaciclib	Eli Lilly	Phase 1	21
DSP-0390	Sumitomo Pharma	Phase 1	33
Mirvetuximab soravtansine + Carboplatin	AbbVie	Phase 2	39
Mirvetuximab Soravtansine	AbbVie	Phase 2	42
Acalabrutinib + Obinutuzumab	AstraZeneca	Phase 2	42
Olaparib Pill + AZD6738	AstraZeneca	Phase 2	35
Efineptakin alfa + Pembrolizumab	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	39
Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel	Merck	Phase 2	35
Cilengitide	Merck	Phase 2	31
Avelumab	Merck	Phase 2	35
Human Papillomavirus vaccine	Merck	Phase 2	35